Ocuvex Therapeutics resubmits Complete Response Letter to USFDA for PDP-716
Written By : Ruchika Sharma
Published On 2025-11-20 10:44 GMT | Update On 2025-11-20 10:44 GMT
Advertisement
Mumbai: Sun Pharma Advanced Research Company Ltd. (SPARC) has announced that Ocuvex Therapeutics Inc. has resubmitted a Complete Response Letter (CRL) to the US Food and Drug Administration (FDA) for the PDP-716 New Drug Application (NDA).
PDP-716 is a novel, once daily, ophthalmic suspension of brimonidine tartrate 0.35%. PDP-716 was developed using SPARC’s proprietary TearAct technology.
The PDP-716 Complete Response resubmission addresses the FDA CRL issued in July 2023, stating unresolved facility inspection-related conditions at a third-party Active Pharmaceutical Ingredient (API) manufacturing facility.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.